These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19550308)

  • 1. Medication adherence and the patient with coronary artery disease: challenges for the practitioner.
    Maddox TM; Ho PM
    Curr Opin Cardiol; 2009 Sep; 24(5):468-72. PubMed ID: 19550308
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the residual risk of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor therapy with combination therapy.
    Polonsky TS; Davidson MH
    Am J Cardiol; 2008 Apr; 101(8A):27B-35B. PubMed ID: 18375238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When statin therapy stops: implications for the patient.
    Daskalopoulou SS
    Curr Opin Cardiol; 2009 Sep; 24(5):454-60. PubMed ID: 19574923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence to support aggressive management of high-density lipoprotein cholesterol: implications of recent imaging trials.
    Taylor AJ
    Am J Cardiol; 2008 Apr; 101(8A):36B-43B. PubMed ID: 18375240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving concepts on benefits and risks associated with therapeutic strategies to raise HDL.
    Shah PK
    Curr Opin Cardiol; 2010 Nov; 25(6):603-8. PubMed ID: 20827180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of a retrospective database analysis of adherence to statin therapy and risk of nonfatal ischemic heart disease in daily clinical practice in Italy.
    Corrao G; Conti V; Merlino L; Catapano AL; Mancia G
    Clin Ther; 2010 Feb; 32(2):300-10. PubMed ID: 20206788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholesterol complacency in Australia: time to revisit the basics of cardiovascular disease prevention.
    Carrington MJ; Retegan C; Johnston CI; Jennings GL; Stewart S
    J Clin Nurs; 2009 Mar; 18(5):678-86. PubMed ID: 19077020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rationale for targeting multiple lipid pathways for optimal cardiovascular risk reduction.
    Ballantyne CM
    Am J Cardiol; 2005 Nov; 96(9A):14K-19K; discussion 34K-35K. PubMed ID: 16291009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Critical evaluation of indications for lipid reduction. Cholesterol value updated--risk counts (interview by Dr. Kirsten Westphal)].
    Motz W
    MMW Fortschr Med; 2003 Oct; 145(41):48. PubMed ID: 14655487
    [No Abstract]   [Full Text] [Related]  

  • 12. Lipid management in the geriatric patient.
    Nair AP; Darrow B
    Endocrinol Metab Clin North Am; 2009 Mar; 38(1):185-206. PubMed ID: 19217519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of preprocedural statin use on procedural myocardial infarction and major cardiac adverse events in percutaneous coronary intervention: a meta-analysis.
    Ebrahimi R; Saleh J; Toggart E; Shah AP; Azmoon S; Babaei H; Lee J; Smith R; Movahed MR; Rubin SA
    J Invasive Cardiol; 2008 Jun; 20(6):292-5. PubMed ID: 18523323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The case for medical treatment in chronic stable coronary artery disease.
    Nash DT
    Arch Intern Med; 2005 Dec 12-26; 165(22):2587-9, discussion 2593-4. PubMed ID: 16344414
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of dyslipidemia in post-infarction: state of the art].
    Borgia MC; Nardi M; Da Ros S; Castellano V
    Clin Ter; 2007; 158(6):523-32. PubMed ID: 18265719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The COACH program produces sustained improvements in cardiovascular risk factors and adherence to recommended medications-two years follow-up.
    Jelinek M; Vale MJ; Liew D; Grigg L; Dart A; Hare DL; Best JD
    Heart Lung Circ; 2009 Dec; 18(6):388-92. PubMed ID: 19648058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery.
    Collard CD; Body SC; Shernan SK; Wang S; Mangano DT; ;
    J Thorac Cardiovasc Surg; 2006 Aug; 132(2):392-400. PubMed ID: 16872968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies to enhance cardiovascular disease prevention in patients with diabetes.
    Anselmino M; Rydén L
    Curr Opin Cardiol; 2009 Sep; 24(5):461-7. PubMed ID: 19574921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular morbidity associated with nonadherence to statin therapy.
    Blackburn DF; Dobson RT; Blackburn JL; Wilson TW
    Pharmacotherapy; 2005 Aug; 25(8):1035-43. PubMed ID: 16207093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.